All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Alpha Cognition

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy

Contact the Supplier

Lead Product(s): Alpha-1062

Therapeutic Area: Neurology

Highest Development Status: Phase I/ Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2020

Details:

U.S. FDA agreed upon a clinical and regulatory pathway for the approval of Alpha-1062 and has suggested that a single pivotal trial, scheduled for mid-2021.